Lumira Ventures partners with exceptional entrepreneurs to build life science companies that transform the lives of patients worldwide.
November 16, 2021
Maryland-based biotech company Deka Biosciences ("Deka") today announced that it has successfully closed a USD 20 Million Series A financing with a syndicate of life science investors led... Learn More
November 5, 2021
Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today... Learn More
November 3, 2021
Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced the successful... Learn More
LAVA Medtech Acquisition Corp. Announces Closing of $115 Million Initial Public Offering Including Full Exercise of the Over-Allotment Option
October 29, 2021
LAVA Medtech Acquisition Corp. (the “Company”) today announced the closing of its initial public offering of 11,500,000 units at a price of $10.00 per unit, including 1,500,000 units... Learn More
Our investment team of 12 professionals has over 225 years of collective experience founding, managing and investing in healthcare and life sciences companies. We value collaboration, creativity and challenging conventional wisdom.
Lumira donates a portion of partner time and profits to support the research, translational medicine and healthcare access missions of over a dozen leading healthcare foundations.
"Lumira's philanthropic vision of leveraging research, resources and knowledge to improve the lives of patients will strengthen St. Michael's ability to accelerate the pace."
Dr. Arthur Slutsky | Vice-President
Vice-President of Research at St. Michael's Hospital
"Lumira's model provides a new pathway for philanthropy to partner with investors in advancing healthcare innovation."
Barbara Grantham | President & Ceo
VGH & UBC Hospital Foundation
“This distinctive approach to supporting innovation is very creative, very much needed and very much appreciated by Princess Margaret and University Health Network.”
Paul Alofs | President & Ceo
Princess Margaret Cancer Foundation
Our team is strategically situated across North America to identify innovative companies within and outside the traditional start-up hubs, and help them access capital, talent and strategic partners.
141 Adelaide Street
Canada, M5H 3L5
3, Place Ville Marie
Bureau 12350, Niveau L
Canada, H3B 0E7
1021 West Hastings Street,
Canada, V6E 0C3
303 Wyman Street